This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

 
                                               Enliven Therapeutics, Inc. 
                                 Selected Condensed Consolidated Financial Information 
                                         (in thousands, except per share data) 
                                                      (unaudited) 
 
Statements of 
Operations                    Three Months Ended September 30,                  Nine Months Ended September 30, 
                      ------------------------------------------------  ------------------------------------------------ 
                               2024                     2023                     2024                     2023 
                      -----------------------  -----------------------  -----------------------  ----------------------- 
Operating 
expenses: 
   Research and 
    development          $             21,258     $             19,606     $             60,054     $             46,669 
   General and 
    administrative                      5,810                    4,642                   17,604                   14,131 
Total operating 
 expenses                              27,068                   24,248                   77,658                   60,800 
                      -----------------------  -----------------------  -----------------------  ----------------------- 
Loss from operations                 (27,068)                 (24,248)                 (77,658)                 (60,800) 
Other income 
 (expense), net                         3,912                    3,479                   11,814                    8,586 
Net loss                $            (23,156)    $            (20,769)    $            (65,844)    $            (52,214) 
                      =======================  =======================  =======================  ======================= 
Net loss per share, 
 basic and diluted    $                (0.48)  $                (0.51)  $                (1.43)  $                (1.55) 
Weighted-average 
 shares outstanding, 
   basic and 
 diluted                               48,267                   41,031                   46,137                   33,665 
 
Balance Sheets                                                               September 30,             December 31, 
                                                                                 2024                     2023 
                                                                        -----------------------  ----------------------- 
Assets 
Current assets: 
   Cash, cash equivalents and marketable securities                         $           291,834      $           253,148 
   Restricted cash                                                                           54                       54 
   Prepaid expenses and other current assets                                              5,109                    2,949 
   Contingent value right asset                                                              --                   10,000 
                                                                        -----------------------  ----------------------- 
Total current assets                                                                    296,997                  266,151 
Property and equipment, net                                                                 549                      742 
Operating lease right-of-use assets                                                          81                      320 
Deferred offering costs                                                                     563                      563 
Other long-term assets                                                                    7,240                    4,091 
Total assets                                                                $           305,430      $           271,867 
                                                                        =======================  ======================= 
Liabilities and Stockholders' Equity 
Current liabilities: 
   Accounts payable                                                      $                1,019  $                   532 
   Accrued expenses and other current liabilities                                        16,008                   15,362 
   Contingent value right liability                                                          --                   10,000 
                                                                        -----------------------  ----------------------- 
Total current liabilities                                                                17,027                   25,894 
Long-term liabilities                                                                        --                       67 
                                                                        -----------------------  ----------------------- 
Total liabilities                                                                        17,027                   25,961 
                                                                        -----------------------  ----------------------- 
Stockholders' equity                                                                    288,403                  245,906 
Total liabilities and stockholders' equity                                  $           305,430      $           271,867 
                                                                        =======================  ======================= 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-reports-third-quarter-financial-results-and-provides-a-business-update-302304281.html

SOURCE Enliven Therapeutics, Inc.

/CONTACT: Investors, ir@enliventherapeutics.com; Media, media@enliventherapeutics.com

(END) Dow Jones Newswires

November 13, 2024 16:05 ET (21:05 GMT)